{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103"}]}],"title":"HMG COA REDUCTASE INHIBITORS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"PLATELET AGGREGATION INHIBITORS (EXCLUDING HEPARIN)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"ACE INHIBITORS, PLAIN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"VITAMIN D AND ANALOGUES"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"ANGIOTENSIN II ANTAGONISTS, PLAIN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"BETA BLOCKING AGENTS, SELECTIVE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"DIHYDROPYRIDINE DERIVATIVES"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"PROTEIN PUMP INHIBITORS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"DRUGS USED IN ERECTILE DYSFUNCTION"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"MULTIVITAMINS, PLAIN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"BIGUANIDES"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"THIAZIDES, PLAIN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"OTHER ANTIDEPRESSANTS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"ALPHA-ADRENORECEPTOR ANTAGONISTS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"PROPIONIC ACID DERIVATIVES"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"THYROID HORMONES"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"}],"units":"Participants"}],"description":"Medications will be coded using the WHO drug dictionary. The medications are summarized by ATC level 4 category and presented as number and percentage of participants.\n\nResults are presented where the percentage of participants within an ATC level 4 category is \\>5.0.","groups":[{"description":"Participants with suspected recurrence of prostate cancer and negative or equivocal findings per institutional standard of care conventional imaging were enrolled to receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL injection followed by a single PET/CT scan acquired 1 to 2 hours post-dosing.","id":"OG000","title":"18F-DCFPyL Injection"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Set includes all participants who received any amount of 18F-DCFPyL.","reportingStatus":"POSTED","timeFrame":"From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.","title":"Collection of Concomitant Medications (Safety Outcome Measure)","type":"SECONDARY","unitOfMeasure":"Participants"}